Utilizing small molecules R1-1 and B02 to inhibit RAD51, which plays an important role in homologous recombination, has led to radiotherapy and chemotherapy sensitization in glioma and breast cancer, respectively. This evidence concerns the gene RAD51 and central nervous system cancer.